NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Current Liabilities | - | - | - | - | - |
What is the latest Current Liabilities ratio of NATH BIOGENES (INDIA) ?
| Year | Current Liabilities |
|---|---|
| Mar2025 | - |
| Mar2024 | - |
| Mar2023 | - |
| Mar2022 | - |
| Mar2013 | - |
How is Current Liabilities of NATH BIOGENES (INDIA) Trending?
| Years | Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | - | 0 | |
| Mar2024 | - | 0 | |
| Mar2023 | - | 0 | |
| Mar2022 | - | 0 | |
| Mar2013 | - | - | |
Compare Current Liabilities of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹301.3 Cr | -4.5% | -7.8% | -8.3% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹12,989.8 Cr | 1.1% | -9.5% | -24.8% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹5,250.4 Cr | -4.6% | -4% | 21.7% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,873.3 Cr | -1.7% | -8.9% | -20.8% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,167.3 Cr | -4.3% | -10.7% | -22.8% | Stock Analytics | |
| INDO US BIOTECH | ₹253.1 Cr | 1.9% | -3.4% | -47.6% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | -4.5% |
-7.8% |
-8.3% |
| SENSEX | 0.8% |
1% |
9.9% |
You may also like the below Video Courses